3NK.F ALPHAMAB ONCOLO.DL-000002

Healthcare Biotechnology Frankfurt Exchange
0.6850 EUR
Close of Nov 11, 2026
0.6700 1.28
Market cap
EUR 661M
P/E
-
P/B
2.98x
ROE
-6.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 3NK.F undervalued?

Graham number

The Graham number of ALPHAMAB ONCOLO.DL-000002 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALPHAMAB ONCOLO.DL-000002 fundamental analysis

No fundamental analysis for ALPHAMAB ONCOLO.DL-000002 yet.

ALPHAMAB ONCOLO.DL-000002 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALPHAMAB ONCOLO.DL-000002

Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal gr…

Full company profile